WoundReference improves clinical decisions
 Choose the role that best describes you
Papanas N, Maltezos E, et al.
The international journal of lower extremity wounds. Date of publication 2007 Mar 1;volume 6(1):37-53.
1. Int J Low Extrem Wounds. 2007 Mar;6(1):37-53. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Papanas N(1), Maltezos E. Author information: (1)Outpatient Department of Diabetes, Obesity and Metabolism at the Second Department of Internal Medicine, Democritus University of Thrace, Greece. papanasnikos@yahoo.gr Foot ulcers remain a common problem, leading to increased morbidity in patients with diabetes. Despite the progress that has been achieved in revascularization techniques as well as in off-loading to relieve high-pressure areas, diabetic foot wounds remain a clinical challenge. Growth factors are a major technological advance that promised to change the face of wound healing. The most important of growth factors are recombinant human platelet-derived growth factor-BB and granulocyte colony-stimulating factor. The former has been approved by the FDA for the treatment of neuropathic ulcers when there is adequate blood supply. The latter is less demonstrably useful. Advances include methods of delivering growth factors. DOI: 10.1177/1534734606298416 PMID: 17344201 [Indexed for MEDLINE]
Appears in following Topics:
Diabetic Foot Ulcer - Treatment